로딩 중…
StockDiggingStockDigging

LeMaitre Vascular, Inc.

LMAT· NASDAQ
$81.24+0.37%
2026-11-02

Financials

Valuation Metrics

LeMaitre Vascular, Inc.'s Market Cap is $1.86B. At end of 2025 it was $1.84B. Ranked #2005 of 3,116 in US market (top 64%), #761 of 1,472 on NASDAQ (top 52%), #125 of 203 in Health Care Equipment & Services (top 62%) by Market Cap.

Investment Metrics(as of 2026-11-02)

MetricValue
Size
Market Cap$1.86B
Revenue$262M
Net Income$66M
Total Assets$641M
Net Assets$420M
Employees646
Value
P/E28.27x
P/B4.42x
PEG0.72x
P/S7.07x
EV/EBITDA20.76x
FCF Yield3.98%
Profitability
ROE15.62%
ROA10.25%
Op. Margin29.46%
Revenue Growth11.85%
Earnings Growth39.39%
Financial Health
Debt Ratio52.39%
Total Debt$190M
FCF$74M
Cash$27M
Current Ratio16.31x
Net Debt/EBITDA1.68x
Dividend
Div. Yield1.10%
Div. Growth24.91%
Performance
1Y Return-5.98%
1M Return2.89%
From 52W High-31.22%
1Y MDD-32.87%
Trading
Volume208,265 shares
Trading Value$17M
Per Share
EPS$2.87
BPS$18.40

Company Info

CEO Mr. George W. LeMaitre
Employees 646
HQ Burlington, United States

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.